Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma

RegulatoryapprovedHBM7575/SKB575Positive

AI Analysis

Summary

Harbour BioMed and Kelun-Biotech announced NMPA approval of the IND application for HBM7575/SKB575, an antibody therapeutic candidate for asthma treatment. The approval enables clinical development of the drug in China.

Outcome Details

NMPA approval of IND application

Importance:6/10

Sentiment:

0.70

NMPA approvalIND applicationantibody therapeuticasthmaimmunology

Related Companies

$DFPH $GBCYD

Read the original article

Published by PR Newswire Pharma on July 15, 2026 10:01 AM

Read Original